


PHARMACEUTICAL 2020



Actinium Pharmaceuticals Inc. Rank 334 of 362





PHARMACEUTICAL 2020



Actinium Pharmaceuticals Inc. Rank 334 of 362

The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 516% points.

The company's Economic Capital Ratio, given in the ranking table, is -935%, being 632% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	10,088
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,344
Liabilities, Non-Current	0
Other Assets	1,470
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	682
Other Net Income	172
Property and Equipment	113
Research and Development	16,550
Revenues	0
Selling, General and Administrative Expense	5,522

Output Variable	Value in 1000 USD
Assets	11,670
Liabilities	6,026
Expenses	22,071
Stockholders Equity	5,644
Net Income	-21,899
Comprehensive Net Income	-21,899
Economic Capital Ratio	-935%